EKF Diagnostics Holdings plc (LON:EKF - Get Free Report)'s share price passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 23.93 ($0.32) and traded as high as GBX 26.90 ($0.36). EKF Diagnostics shares last traded at GBX 25.20 ($0.34), with a volume of 2,253,335 shares traded.
EKF Diagnostics Stock Performance
The company has a current ratio of 4.60, a quick ratio of 1.77 and a debt-to-equity ratio of 0.34. The firm has a market cap of £120.01 million, a PE ratio of 25.13 and a beta of 0.57. The stock's 50 day moving average price is GBX 21.44 and its 200 day moving average price is GBX 23.85.
EKF Diagnostics (LON:EKF - Get Free Report) last announced its quarterly earnings results on Tuesday, March 25th. The company reported GBX 1.38 ($0.02) earnings per share (EPS) for the quarter. EKF Diagnostics had a return on equity of 7.03% and a net margin of 9.37%. As a group, equities analysts forecast that EKF Diagnostics Holdings plc will post 2.2987842 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other news, insider Gavin T. Jones acquired 50,000 shares of the company's stock in a transaction dated Tuesday, March 25th. The shares were bought at an average price of GBX 22 ($0.29) per share, for a total transaction of £11,000 ($14,692.13). 5.24% of the stock is currently owned by insiders.
About EKF Diagnostics
(
Get Free Report)
EKF is an AIM-listed global diagnostics business focussed on:
● Point-of-Care analysers in the key areas of Hematology and Diabetes
● Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.
EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.
Featured Stories
Before you consider EKF Diagnostics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and EKF Diagnostics wasn't on the list.
While EKF Diagnostics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
